Sucampo Announces Completion of Patient Enrollment in a Phase 3 Clinical Study of Unoprostone Isopropyl for Retinitis Pigmentosa
October 21, 2013 20:00 ET
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Sucampo AG, a subsidiary of Sucampo Pharmaceuticals, Inc. (Nasdaq:SCMP) ("Sucampo"), today announced that its development partner, R-Tech Ueno, Ltd....
Second Sight Reaches Middle East: Another Major Milestone for Blind People With Retinitis Pigmentosa
March 06, 2013 03:00 ET
|
Second Sight Medical Products Inc.
LAUSANNE, Switzerland, and RIYADH, Saudi Arabia, March 6, 2013 (GLOBE NEWSWIRE) --
Dr. Fernando Arevalo, Adjunct Professor of Ophthalmology at Wilmer Eye Institute (Retina Division) at Johns...
Foundation Fighting Blindness Invests $8.25 Million in Six Gene Therapy Research Projects Poised for Clinical Trials
October 31, 2011 13:05 ET
|
Foundation Fighting Blindness
COLUMBIA, Md., Oct. 31, 2011 (GLOBE NEWSWIRE) -- The Foundation Fighting Blindness, a national nonprofit dedicated to advancing sight-saving research, announces an $8.25 million investment in six new...